Rx drug ads to consumers
Consulting firm Scott-Levin Associates reports that drug manufacturers spent $50 mil. on consumer drug advertising in 1987, twice as much as in 1986. Merrell Dow was the leader in direct-to-consumer ad spending with its campaign for Seldane. Of consumers recalling the Seldane ads, the Scott-Levin survey found that 18% discussed the drug with an MD or pharmacist. Scott-Levin's study also found that in a recent consumer survey, two-thirds recalled exposure to a drugstore ad pertaining to the lower cost of generic drugs, with 43% receiving a generic prescription as result.
You may also be interested in...
Amwell’s increased the size of its IPO and raised $742m when it sold 41.2 million shares at $18 each.
Pink Sheet Podcast: COVID-19 Stresses Manufacturing, Vaccine Placebo Controls, Thorny FDA Precedents
Pink Sheet reporters and editor discuss the pandemic’s effects on non-coronavirus-related product manufacturing, US FDA efforts to ensure vaccine sponsors maintain placebo controls once a product is available, and precedents that burden the agency.
While Accord HealthCare has convinced the European Medicines Agency that its rivaroxaban generic should be approved in the EU, Bayer has warned that patent protection for Xarelto continues until at least late 2023. The EMA this week also recommend approval for a number of other new drugs.